Drug Delivery

KeraStat Gel as a Drug Delivery Vehicle

Local, tissue-specific drug delivery is a growing need for many therapeutic and regenerative medicine strategies.  Unfortunately, the majority of current biomaterial delivery vehicles are unable to provide desirable release kinetics, formulation options, degradation profiles, and/or biocompatibility characteristics necessary for successful drug delivery.  KeraNetics is developing an ideal solution to these problems with a system that resists enzymatic degradation and that can be formulated into a wide variety of carrier options with varying viscoelastic properties.  These formulations can also be tailored to provide short- or long-term release profiles for a wide range of drug chemistries.

Topical Delivery of Antibiotics in Infected Wounds

Wounds infected with resistant bacteria are a growing problem. Kalaroma estimates that there is a $1.163B annual US market revenue for infected wounds. KeraNetics has in its R&D pipeline a next generation advanced wound care product that provides topical antibiotic drug delivery for prevention and treatment of infected wounds.

Pre-Clinical Studies Show:

  • Controlled release delivery system for a variety of drugs with keratin plus a varity chemical antibiotics including: ciprofloxacin, neomycin, and others can control the growth of MRSA.

Topical Delivery of Opiates for Pain Management in Wounds

The systemic use of opiates to control pain is a nationwide problem with resulting addiction. BCC estimates that there is a $3.5B annual market revenue for post procedure anesthetics. KeraNetics has in its R&D pipeline a Next Generation topical drug delivery for non-systemic pain management for advance wound care.

Pre-Clinical Studies Show:

  • Pre-clinical studies have shown that keratin plus opiates reduce pain non-systemically.